mary claire haver glp 1 dr and How Mary Claire Haver Became the Queen of Menopause Ready to tackle stubborn midlife

International Journal of Molecular Sciences , 22(9), 5010

For subcutaneous administration, 250-500 mcg per day represents the standard range, with some protocols using 300 mcg as a target dose

Furthermore, GLP-1 receptor agonists also show promise in the targeting of other disorders, including neurodegenerative disorders, metabolic liver disease, heart failure, and cancer

Phase 2 Trial Design Participants: 338 adults with obesity (BMI 30) or overweight with comorbidities (BMI 27), without diabetes Duration: 48 weeks Dosing groups: Placebo, 1mg, 4mg, 8mg, or 12mg weekly (with gradual dose escalation over 20-24 weeks) Primary endpoint: Percentage change in body weight from baseline Beyond Weight Loss: Metabolic Improvements Beyond weight loss, the 12mg dose also improved several cardiometabolic markers: Blood pressure: Systolic BP decreased by 7.4 mmHg (clinically significant reduction) Lipids: Triglycerides fell 30%, HDL cholesterol increased 8% Glucose control: HbA1c decreased 0.4% even in participants without diabetes Liver health: Markers of fatty liver disease (ALT, AST) improved significantly Inflammation: C-reactive protein (CRP) decreased, indicating reduced systemic inflammation What this means: Retatrutide appears to improve the metabolic dysfunction behind obesity-related diseases, not just the weight itself